Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Clinical trial NCT02810418 · COMPLETED
Trial details
- NCT number
- NCT02810418
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-03
- Primary completion
- 2019-01-02
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.